PAQR6 as a prognostic biomarker and potential therapeutic target in kidney renal clear cell carcinoma
2024

PAQR6 as a Biomarker in Kidney Cancer

Sample size: 532 publication 10 minutes Evidence: high

Author Information

Author(s): Zou Tao, Jia Zongming, Wu Jixiang, Liu Xuxu, Deng Minghao, Zhang Xuefeng, Lin Yuxin, Ping Jigen

Primary Institution: The First Affiliated Hospital of Soochow University

Hypothesis

PAQR6 may serve as a prognostic biomarker and therapeutic target in kidney renal clear cell carcinoma (KIRC).

Conclusion

Elevated PAQR6 expression is linked to poor prognosis in KIRC patients, suggesting its potential as a prognostic biomarker and therapeutic target.

Supporting Evidence

  • PAQR6 was identified as a critical oncogene through WGCNA and differential gene expression analysis.
  • High PAQR6 expression correlated with lower overall survival rates in KIRC patients.
  • Functional enrichment analysis showed PAQR6's involvement in angiogenesis and pluripotent stem cell differentiation.
  • Immune infiltration analysis indicated PAQR6's role in the immune microenvironment of KIRC.

Takeaway

This study found that a protein called PAQR6 is found in higher amounts in kidney cancer, and this might mean that patients with more PAQR6 could have worse outcomes.

Methodology

The study used differential gene expression analysis, WGCNA, immune infiltration analysis, and various assays to investigate PAQR6's role in KIRC.

Limitations

The study primarily relies on computational analyses and requires further in vivo validation.

Participant Demographics

The study included 532 KIRC samples and 72 normal samples from TCGA-KIRC dataset.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.3389/fimmu.2024.1521629

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication